Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose

International Journal of Antimicrobial Agents

Volumn 27, Issue 1, 2006, Pages 7-14

  Wagenlehner, Florian M E ^a   Kinzig Schippers, Martina ^b   Tischmeyer, Uwe ^a   Wagenlehner, Christine ^a   Sörgel, Fritz ^b,c   Dalhoff, Axel ^d   Naber, Kurt G ^a  

^a Urologische Klinik   (Germany)

^b IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d BAYER AG   (Germany)

Author keywords

Ciprofloxacin XR; Levofloxacin; Pharmacokinetic parameters; Plasma and urine concentrations; Urinary tract infections

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CONCENTRATING CAPACITY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; URINARY EXCRETION; URINARY TRACT INFECTION; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; CROSS-OVER STUDIES; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OFLOXACIN;

EID: 29944437033     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.09.014     Document Type: Article

References (25)

1. B. Foxman Epidemiology of urinary tract infections: incidence, morbidity, and economic costs Am J Med 113 Suppl. 1A 2002 5 13
2. A.C. Gales, R.N. Jones, and K.A. Gordon Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998) J Antimicrob Chemother 45 2000 295 303
3. T. Mazzulli Resistance trends in urinary tract pathogens and impact on management J Urol 168 2002 1720 1722
4. F.M.E. Wagenlehner, A. Niemetz, A. Dalhoff, and K.G. Naber Spectrum and antibiotic resistance of uropathogens from hospitalized patients with urinary tract infections 1994-2004 Int J Antimicrob Agents 19 2002 557 564
5. J.W. Warren, E. Abrutyn, J.R. Hebel, J.R. Johnson, A.J. Schaeffer, and W.E. Stamm Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA) Clin Infect Dis 29 1999 745 758
6. K.G. Naber, B. Bergman, and M.C. Bishop EAU guidelines for the management of urinary and male genital tract infections Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU) Eur Urol 40 2001 576 588
7. S.D. Fihn Clinical practice. Acute uncomplicated urinary tract infection in women N Engl J Med 349 2003 259 266
8. T.M. Hooton The current management strategies for community-acquired urinary tract infection Infect Dis Clin North Am 17 2003 303 332
9. G. Kahlmeter An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO SENS project J Antimicrob Chemother 51 2003 69 76
10. B.J. Barnett, and D.S. Stephens Urinary tract infection: an overview Am J Med Sci 314 1997 245 249
11. A.C. Fluit, M.E. Jones, F.J. Schmitz, J. Acar, R. Gupta, and J. Verhoef Antimicrobial resistance among urinary tract infection (UTI) isolates in Europe: results from the SENTRY Antimicrobial Surveillance Program 1997 Antonie Van Leeuwenhoek 77 2000 147 152
12. W.O. Roberts Urinary tract infections and the cost of antimicrobial resistance. A special report, Healthcare Information Programs Postgrad Med 2001 1 29
13. K.A. Gordon, and R.N. Jones Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000) Diagn Microbiol Infect Dis 45 2003 295 301
14. D.C. Henry Jr., R.B. Bettis, and E. Riffer Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women Clin Ther 24 2002 2088 2104
15. D.A. Talan, K.G. Naber, J. Palou, and D. Elkharrat Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections Int J Antimicrob Agents 23 2004 54 66
16. Theil FP, Frede M, Stass H. Population pharmacokinetic characterization of the new Ciprofloxacin MR formulation with ciprofloxacin IR. Clin Microbiol Infect 2003;9(Suppl. 1):abstract 1228.
17. S. Krĉmery, and K.G. Naber Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections German Ciprofloxacin UTI Study Group Int J Antimicrob Agents 11 1999 133 138
18. I.M. Gould, K. Milne, and C. Jason Concentration-dependent bacterial killing, adaptive resistance and post-antibiotic effect of ciprofloxacin alone and in combination with gentamicin Drugs Exp Clin Res 16 1990 621 628
19. H. Lode, K. Borner, and P. Koeppe Pharmacodynamics of fluoroquinolones Clin Infect Dis 27 1998 33 39
20. D.A. Talan, W.I. Klimberg, L.E. Nicolle, J. Song, S.F. Kowalsky, and D.A. Church Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis J Urol 171 2004 734 739
21. T. Goto, Y. Nakame, M. Nishida, and Y. Ohi Bacterial biofilms and catheters in experimental urinary tract infection Int J Antimicrob Agents 11 1999 227 231
22. T. Deguchi, M. Kuriyama, and S. Maeda Electron microscopic study of acute retrograde pyelonephritis in mice Urology 35 1990 423 427
23. G.R. Chippendale, J.W. Warren, A.L. Trifillis, and H.L.T. Mobley Internalization of Proteus mirabilis by human renal epithelial cells Infect Immun 62 1994 3115 3121
24. M.A. Mulvey, J.D. Schilling, and S.J. Hultgren Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection Infect Immun 69 2001 4572 4579
25. F. Pea, F. Pavan, and E. Di Qual Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia J Chemother 15 2003 563 567